Insmed (INSM) Revenue Growth (1y) (2011 - 2026)
Insmed (INSM) Revenue Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,200.25 Bn | 66,199.96 Bn | - | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.75 Bn | 466.96 Bn | 1.35 Bn | 35.46% |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | 7.82% |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | 19.04% |
| 7 | Belite Bio | 62.43 Bn | 62.43 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | 64.03% |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 96.43% |
| 10 | Insmed | 22.86 Bn | 21.64 Bn | 258.54 Mn | 229.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 229.62% |
| Dec 31, 2025 | 152.62% |
| Sep 30, 2025 | 52.36% |
| Jun 30, 2025 | 18.90% |
| Mar 31, 2025 | 22.94% |
| Dec 31, 2024 | 24.79% |
| Sep 30, 2024 | 18.15% |
| Jun 30, 2024 | 16.98% |
| Mar 31, 2024 | 15.77% |
| Dec 31, 2023 | 41.13% |
| Sep 30, 2023 | 16.75% |
| Jun 30, 2023 | 18.41% |
| Mar 31, 2023 | 22.80% |
| Dec 31, 2022 | 5.66% |
| Sep 30, 2022 | 44.86% |
| Jun 30, 2022 | 43.77% |
| Mar 31, 2022 | 32.06% |
| Dec 31, 2021 | 35.52% |
| Sep 30, 2021 | 7.14% |
| Jun 30, 2021 | 6.76% |